Place des bêta-agonistes de longue durée dans le traitement de l'asthme bronchique

Long acting beta2-agonists (LABA) are one of the most widely prescribed anti-asthmatic therapies. Nevertheless, their chronic utilization has been associated in large clinical studies with severe asthma exacerbations and asthma-related deaths raising concern about their safety. Awaiting further evidence to definitely identify susceptible subgroups, LABA should be used with caution. Inhaled corticosteroids (ICS) is the preferred asthma controller option and LABA should be used only in association with ICS in patients insufficiently controlled under ICS therapy